- Home
- AMIX vs LIXT Comparison
AMIX vs LIXT Comparison
Compare AMIX & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- LIXT
- Stock Information
- Founded
- AMIX 2014
- LIXT 2005
- Country
- AMIX United States
- LIXT United States
- Employees
- AMIX N/A
- LIXT N/A
- Industry
- AMIX
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- AMIX
- LIXT Health Care
- Exchange
- AMIX NYSE
- LIXT Nasdaq
- Market Cap
- AMIX 4.9M
- LIXT 4.1M
- IPO Year
- AMIX N/A
- LIXT N/A
- Fundamental
- Price
- AMIX $1.95
- LIXT $1.38
- Analyst Decision
- AMIX Strong Buy
- LIXT
- Analyst Count
- AMIX 1
- LIXT 0
- Target Price
- AMIX $5.00
- LIXT N/A
- AVG Volume (30 Days)
- AMIX 347.1K
- LIXT 16.9K
- Earning Date
- AMIX 05-30-2025
- LIXT 05-12-2025
- Dividend Yield
- AMIX N/A
- LIXT N/A
- EPS Growth
- AMIX N/A
- LIXT N/A
- EPS
- AMIX N/A
- LIXT N/A
- Revenue
- AMIX N/A
- LIXT N/A
- Revenue This Year
- AMIX N/A
- LIXT N/A
- Revenue Next Year
- AMIX N/A
- LIXT N/A
- P/E Ratio
- AMIX N/A
- LIXT N/A
- Revenue Growth
- AMIX N/A
- LIXT N/A
- 52 Week Low
- AMIX $1.52
- LIXT $1.02
- 52 Week High
- AMIX $75.80
- LIXT $3.50
- Technical
- Relative Strength Index (RSI)
- AMIX 50.80
- LIXT 56.57
- Support Level
- AMIX $1.67
- LIXT $1.26
- Resistance Level
- AMIX $1.96
- LIXT $1.62
- Average True Range (ATR)
- AMIX 0.21
- LIXT 0.11
- MACD
- AMIX -0.01
- LIXT 0.02
- Stochastic Oscillator
- AMIX 24.35
- LIXT 50.00
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.